AAP
BCAB icon

Arax Advisory Partners’s BioAtla BCAB Stock Holding History

Arax Advisory Partners’s Portfolio BCAB Stock Details BCAB Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q4 		– Sell
-34
Closed -$2.98K – 2466
2024
Q3 		$2.98K Hold
34
– – ﹤0.01% 1915
2024
Q2 		$2.32K Buy
+34
New +$4.04K ﹤0.01% 1919

Other funds holding BCAB

AFM
Anson Funds Management Dallas, Texas $2.29B AUM 370.24% 1-Year Est. Return
ACA
Acorn Capital Advisors New York $352M AUM 299.18% 1-Year Est. Return
HCM
Highbridge Capital Management New York $3.09B AUM 31.19% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
TCM
Tang Capital Management San Diego, California $1.97B AUM 125.1% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return
BCM
Boxer Capital Management San Diego, California $762M AUM 1,125.36% 1-Year Est. Return
Jacobs Levy Equity Management
Jacobs Levy Equity Management Florham Park, New Jersey $23.8B AUM 25.4% 1-Year Est. Return

Arax Advisory Partners's BCAB Position: Q4 2024 in Review

Arax Advisory Partners sold out of BioAtla (BCAB) in Q4 2024, closing a stake of 34 shares — an estimated $2.98K sold.

Arax Advisory Partners first reported a position in BCAB in Q2 2024 and held it in 2 quarters. The position peaked at $2.98K in Q3 2024. 67 funds tracked by Wall St. Rank hold BCAB as of Q4 2024.

  • Arax Advisory Partners reported no remaining BioAtla position as of Q4 2024 after selling out during the quarter.
  • Arax Advisory Partners sold 34 BioAtla shares in Q4 2024, an estimated $2.98K.
  • Arax Advisory Partners first reported a position in BioAtla in Q2 2024 and held it in 2 quarters.
  • Arax Advisory Partners's BioAtla position peaked at $2.98K in Q3 2024.
  • 67 funds tracked by Wall St. Rank held BioAtla as of Q4 2024.

Based on Arax Advisory Partners's 13F filing for Q4 2024, filed 5 Feb 2025.